can't find the statistic comparing treatments in medicated versus non-medicated ADHD. The difference between the ADHD and non-ADHD group seems much larger than between the groups of ADHD patients.

Key Points
• Source: Special Care in Dentistry
• Meaning: “This large nonrandomized clinical trial of patients with METex14-skipping NSCLC supports global approvals of tepotinib, enabling clinicians to implement these therapeutic approaches.”
• MET inhibitors are clinically active in patients with MET exon 14 (METex14)-skipping non–small cell lung cancer (NSCLC). Investigators performed a long-term follow-up analysis of the VISION nonrandomized cl8inical trial.
• The nonrandomized VISION phase 2 trial was a multicohort, open-label, multicenter study involving participants with METex14-skipping advanced/metastatic NSCLC (cohorts A and C) between September 2016 and May 2021. Cohort C, with >18 months’ follow-up, was an independent cohort, designed to confirm findings from cohort A (>35 months’ follow-up). The data cutoff was November 20, 2022.
• “Cohort A from the phase 2 VISION nonrandomized clinical trial demonstrated robust and durable clinical activity with tepotinib in patients with MET exon 14 (METex14)-skipping NSCLC,1-3 based on which, tepotinib was approved for use in several countries globally, including by the US Food and Drug Administration (FDA),” wrote the authors.
• The ORR was 55.9% in 18-month follow-up from cohort C (n = 161), while the median duration of response (mDOR) was 20.8 months across treatment lines. These findings concur with findings from cohort A (n = 152). Across cohorts A and C, the ORR was 57.3% and the mDOR of 46.4 months among 164 treatment-naive patients.
• “In patients with baseline BM, tepotinib demonstrated robust systemic and intracranial outcomes, which had comparable clinical benefit to patients without baseline BM [brain metastases]. Aligned with guidelines, this supports the use of brain-penetrating MET inhibitors, providing a systemic therapy alternative to radiation,” the author wrote.
• VISION was a nonrandomized clinical trial, with the confirmatory cohort C possibly impacted by the positive results of cohort A being reported during enrollment. Specifically, the recruitment of patients into cohort C may have been biased to include patients with improved clinical conditions.